[ A21-110] Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Last updated 03.03.2022
Project no.:
A21-110
Commission:
Commission awarded on 15.09.2021 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Adult patients with moderate to severe plaque psoriasis
- Patients who are not candidates for conventional treatment in the framework of an initial systemic therapy: hint of minor added benefit.
- Patients who have had an inadequate response or who have been intolerant to systemic therapy: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2021-12-15.
| Project no. | Title | Status |
|---|---|---|
| A24-64 | Bimekizumab (hidradenitis suppurativa) - Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A22-07 | Bimekizumab (plaque psoriasis) - Addendum to Commission A21-110 | Commission completed |
| A23-61 | Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-62 | Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-60 | Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-03-03 A G-BA decision was published.